Dr. Kaptain presented his work with Toca 511 in glioblastoma at the Annual Meeting of the Society for Neuro-Oncology in November 2015 in San Antonio.
Here are the three links of the abstracts that were published:
- DDEL-08OVERALL SAFETY AND EFFICACY IN SUBJECTS WITH RECURRENT HGG TREATED ACROSS 2 TOCAGEN STUDIES – PROGNOSTIC FACTORS ASSOCIATED WITH SURVIVAL
- DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES
- SURG-10TRANSCRANIAL TOCA 511 FOLLOWED BY TOCA FC IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA (HGG)
